JP6786529B2 - Ｌｐｔ−７２３と免疫チェックポイント阻害剤との組み合わせおよび処置の方法 - Google Patents

Ｌｐｔ−７２３と免疫チェックポイント阻害剤との組み合わせおよび処置の方法 Download PDF

Info

Publication number
JP6786529B2
JP6786529B2 JP2017568190A JP2017568190A JP6786529B2 JP 6786529 B2 JP6786529 B2 JP 6786529B2 JP 2017568190 A JP2017568190 A JP 2017568190A JP 2017568190 A JP2017568190 A JP 2017568190A JP 6786529 B2 JP6786529 B2 JP 6786529B2
Authority
JP
Japan
Prior art keywords
cancer
bristol
item
antibody
lpt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2017568190A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018519324A (ja
JP2018519324A5 (enExample
Inventor
サウラブ サハ，
サウラブ サハ，
リンピン ザン，
リンピン ザン，
シャオヤン マイケル ザン，
シャオヤン マイケル ザン，
Original Assignee
バイオメッド バレー ディスカバリーズ，インコーポレイティド
バイオメッド バレー ディスカバリーズ，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオメッド バレー ディスカバリーズ，インコーポレイティド, バイオメッド バレー ディスカバリーズ，インコーポレイティド filed Critical バイオメッド バレー ディスカバリーズ，インコーポレイティド
Publication of JP2018519324A publication Critical patent/JP2018519324A/ja
Publication of JP2018519324A5 publication Critical patent/JP2018519324A5/ja
Application granted granted Critical
Publication of JP6786529B2 publication Critical patent/JP6786529B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2017568190A 2015-06-29 2016-06-28 Ｌｐｔ−７２３と免疫チェックポイント阻害剤との組み合わせおよび処置の方法 Expired - Fee Related JP6786529B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562186157P 2015-06-29 2015-06-29
US62/186,157 2015-06-29
PCT/US2016/039885 WO2017004079A1 (en) 2015-06-29 2016-06-28 Lpt-723 and immune checkpoint inhibitor combinations and methods of treatment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020152003A Division JP7054547B2 (ja) 2015-06-29 2020-09-10 Ｌｐｔ－７２３と免疫チェックポイント阻害剤との組み合わせおよび処置の方法

Publications (3)

Publication Number Publication Date
JP2018519324A JP2018519324A (ja) 2018-07-19
JP2018519324A5 JP2018519324A5 (enExample) 2019-08-08
JP6786529B2 true JP6786529B2 (ja) 2020-11-18

Family

ID=57609068

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017568190A Expired - Fee Related JP6786529B2 (ja) 2015-06-29 2016-06-28 Ｌｐｔ−７２３と免疫チェックポイント阻害剤との組み合わせおよび処置の方法
JP2020152003A Expired - Fee Related JP7054547B2 (ja) 2015-06-29 2020-09-10 Ｌｐｔ－７２３と免疫チェックポイント阻害剤との組み合わせおよび処置の方法
JP2022007869A Ceased JP2022058714A (ja) 2015-06-29 2022-01-21 Ｌｐｔ－７２３と免疫チェックポイント阻害剤との組み合わせおよび処置の方法
JP2023103633A Pending JP2023120391A (ja) 2015-06-29 2023-06-23 Ｌｐｔ－７２３と免疫チェックポイント阻害剤との組み合わせおよび処置の方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2020152003A Expired - Fee Related JP7054547B2 (ja) 2015-06-29 2020-09-10 Ｌｐｔ－７２３と免疫チェックポイント阻害剤との組み合わせおよび処置の方法
JP2022007869A Ceased JP2022058714A (ja) 2015-06-29 2022-01-21 Ｌｐｔ－７２３と免疫チェックポイント阻害剤との組み合わせおよび処置の方法
JP2023103633A Pending JP2023120391A (ja) 2015-06-29 2023-06-23 Ｌｐｔ－７２３と免疫チェックポイント阻害剤との組み合わせおよび処置の方法

Country Status (5)

Country Link
US (4) US9861621B2 (enExample)
EP (1) EP3313186A4 (enExample)
JP (4) JP6786529B2 (enExample)
HK (1) HK1254954A1 (enExample)
WO (1) WO2017004079A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201322725D0 (en) 2013-12-20 2014-02-05 Immodulon Therapeutics Ltd Cancer therapy
JP6786529B2 (ja) * 2015-06-29 2020-11-18 バイオメッド バレー ディスカバリーズ，インコーポレイティド Ｌｐｔ−７２３と免疫チェックポイント阻害剤との組み合わせおよび処置の方法
SG10201913147WA (en) * 2017-07-11 2020-02-27 Compass Therapeutics Llc Agonist antibodies that bind human cd137 and uses thereof
US11718679B2 (en) 2017-10-31 2023-08-08 Compass Therapeutics Llc CD137 antibodies and PD-1 antagonists and uses thereof
EP3713961A2 (en) 2017-11-20 2020-09-30 Compass Therapeutics LLC Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
KR20200055116A (ko) * 2018-01-10 2020-05-20 보령제약 주식회사 Pi3 키나아제 억제제 및 면역관문 억제제를 포함하는 암의 예방 또는 치료용 약학적 조성물
WO2020002905A1 (en) * 2018-06-25 2020-01-02 Immodulon Therapeutics Limited Cancer therapy
JP7497351B2 (ja) 2018-11-13 2024-06-10 コンパス セラピューティクス リミテッド ライアビリティ カンパニー チェックポイント分子に対する多重特異性結合性構築物およびその使用
WO2022040365A1 (en) * 2020-08-18 2022-02-24 Curators Of The University Of Missouri Compositions and methods of treatment comprising tumor-targeting bacteria and chemotherapy or immunotherapy agent
WO2023091747A1 (en) * 2021-11-22 2023-05-25 Axial Therapeutics, Inc. Modulator compounds, pharmaceutical compositions and uses thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5235033A (en) 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
FI903489A7 (fi) 1988-11-11 1990-07-10 Medical Res Council Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
DE60045706D1 (de) 1999-03-18 2011-04-21 Exiqon As Detektion von genmutationen mittels lna primer
EP2669377A3 (en) 2003-04-17 2015-10-14 Alnylam Pharmaceuticals Inc. Modified iRNA agents
US20050182005A1 (en) 2004-02-13 2005-08-18 Tuschl Thomas H. Anti-microRNA oligonucleotide molecules
CN101031658A (zh) 2004-05-26 2007-09-05 罗塞塔金诺米克斯有限公司 病毒和病毒相关mirna及其用途
WO2006126040A1 (en) 2005-05-25 2006-11-30 Rosetta Genomics Ltd. Bacterial and bacterial associated mirnas and uses thereof
US9856320B2 (en) * 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
RU2675814C2 (ru) * 2013-09-25 2018-12-25 Вертекс Фармасьютикалз Инкорпорейтед 6,7-ДИГИДРО-5Н-ПИРРОЛО[3,4-b]ПИРИДИН-5-ОН, ПОЛЕЗНЫЙ В КАЧЕСТВЕ СЕЛЕКТИВНОГО ИНГИБИТОРА ФОСФАТИДИЛИНОЗИТОЛ-3-КИНАЗЫ-ГАММА
EP3134546A4 (en) * 2014-04-24 2017-12-06 Dana-Farber Cancer Institute, Inc. Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response
JP2018521015A (ja) * 2015-06-01 2018-08-02 メイン・メデイカル・センター・リサーチ・インステイテユート 免疫チェックポイント阻害薬の治療活性の増強
JP6786529B2 (ja) * 2015-06-29 2020-11-18 バイオメッド バレー ディスカバリーズ，インコーポレイティド Ｌｐｔ−７２３と免疫チェックポイント阻害剤との組み合わせおよび処置の方法
DK3858859T3 (da) * 2015-07-14 2025-12-15 Bristol Myers Squibb Co Fremgangsmåde til behandling af kræft under anvendelse af en immun checkpointinhibitor; antistof som binder til programmeret død-1 receptor (pd-1) eller programmeret død ligand 1 (pd-l1)
JO3620B1 (ar) * 2015-08-05 2020-08-27 Amgen Res Munich Gmbh مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
WO2017083595A1 (en) * 2015-11-10 2017-05-18 Massachusetts Institute Of Technology Complexes comprising a platinum compound and an immune checkpoint inhibitor and related methods

Also Published As

Publication number Publication date
US10485796B2 (en) 2019-11-26
EP3313186A1 (en) 2018-05-02
JP7054547B2 (ja) 2022-04-14
JP2018519324A (ja) 2018-07-19
JP2021004245A (ja) 2021-01-14
JP2022058714A (ja) 2022-04-12
JP2023120391A (ja) 2023-08-29
US20200323831A1 (en) 2020-10-15
US9861621B2 (en) 2018-01-09
US11033537B2 (en) 2021-06-15
HK1254954A1 (zh) 2019-08-02
US10716782B2 (en) 2020-07-21
WO2017004079A1 (en) 2017-01-05
US20170007587A1 (en) 2017-01-12
EP3313186A4 (en) 2019-04-03
US20200078342A1 (en) 2020-03-12
US20180117020A1 (en) 2018-05-03

Similar Documents

Publication Publication Date Title
JP7054547B2 (ja) Ｌｐｔ－７２３と免疫チェックポイント阻害剤との組み合わせおよび処置の方法
JP7252644B2 (ja) 腫瘍を治療するための組み合わせ物およびキット
JP6861418B2 (ja) ヒトｔ細胞免疫グロブリン及びｉｔｉｍドメイン（ｔｉｇｉｔ）に特異的な抗体
JP2020138972A (ja) 疾患および障害の処置においてレナラーゼを制御する組成物および方法
TWI771372B (zh) Wnt抑制劑與抗-pd-1抗體分子組合之給藥方案
JP2021169511A (ja) 免疫療法用組み合わせ組成物
JP2020500179A (ja) 免疫チェックポイント阻害剤と組み合わせた治療的使用のための抗ｂａｇ３抗体
JP7438560B2 (ja) Ｓｍｏタンパク質の特異的エピトープ、これを認知する抗体及びこれを含む組成物
TW202409083A (zh) 抗-tigit抗體及其用途
KR20210118101A (ko) 항암 면역 반응을 유도하는 방법
JP2021535110A (ja) 併用療法
JP2021533090A (ja) 併用療法
JP2020510681A (ja) 抗レナラーゼ抗体および抗ｐｄ−１抗体を用いる、がんを処置するための組成物および方法
US20180134788A1 (en) Methods and Pharmaceutical Compositions (NTSR1 Inhibitors) for the Treatment of Hepatocellular Carcinomas
CN111886257B (zh) 用于疾病和病症治疗和预防的抗-肾酶抗体
WO2025248505A1 (en) Methods for treating endometrial and ovarian hyperproliferative disorders
WO2015191615A2 (en) Combination therapies using agents that target tumor-associated stroma or tumor cells and alkylating agents
JP2024164038A (ja) 抗ｐｄ－ｌ１抗体およびその使用
HK1237354B (en) Anti-pd-l1 combinations for treating tumors
HK1237354A1 (en) Anti-pd-l1 combinations for treating tumors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190627

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190627

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200610

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200910

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200930

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200910

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201028

R150 Certificate of patent or registration of utility model

Ref document number: 6786529

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees